盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床研究

发布时间：2018-07-31 19:46

【摘要】：目的观察盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床疗效和安全性。方法将92例帕金森病患者随机分为对照组46例和试验组46例。对照组予以司来吉兰片每次5 mg,bid,口服;试验组在对照组治疗的基础上,予以盐酸多奈哌齐片每次5 mg,bid,口服。2组患者均治疗2个月。比较2组患者的临床疗效、帕金森病评分量表(UPDRS)、蒙特利尔认知评估量表(MoCA)和简易精神状态量表(MMSE)评分、Barthel指数、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95.65%(44/46例)和76.09%(35/46例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的UPDRS评分分别为(47.03±7.21),(61.67±7.28)分;MoCA评分分别为(27.04±1.97),(20.67±2.15)分;MMSE评分分别为(25.63±3.57),(22.25±3.64)分;Barthel指数分别为(79.29±9.15),(68.43±9.32)分;SOD分别为(117.54±16.14),(98.43±15.12)kU·L~(-1);MDA分别为(5.13±1.83),(5.96±2.14)μmol·L~(-1);GSH分别为(47.66±8.57),(35.27±8.35)μmol·L~(-1),差异均有统计学意义(P0.05)。2组患者的药物不良反应以口干、睡眠障碍、恶心、腹泻、食欲减退为主,试验组和对照组的药物不良反应发生率分别为32.61%和23.91%,差异无统计学意义(P0.05)。结论盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床疗效显著,其能显著提高患者的认知功能、日常生活能力和精神状态,减轻氧化应激水平,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Donepezil Hydrochloride (Donepezil Hydrochloride) combined with selegilan tablets in the treatment of Parkinson's disease. Methods 92 patients with Parkinson's disease were randomly divided into control group (n = 46) and experimental group (n = 46). In the control group, 5 mg bid was given each time, while in the experimental group, the dosage of Donepezil hydrochloride was 5 mg bid each time, and the patients in the 2 groups were treated for 2 months on the basis of the treatment in the control group. To compare the clinical efficacy of the two groups, (UPDRS), Montreal Cognitive Assessment scale (MoCA) and Mini-Mental State scale (MMSE) were used to evaluate the clinical efficacy of the two groups. Superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), and adverse drug reactions. Results after treatment, the total effective rates of the experimental group and the control group were 95.65% (44 / 46 cases) and 76.09% (35 / 46 cases), respectively. The difference was statistically significant (P0.05). After treatment, 璇曢獙缁勫拰瀵圭収缁勭殑UPDRS璇勫垎鍒嗗埆涓，

本文编号：2156646